262 related articles for article (PubMed ID: 25433495)
1. Antipsychotic patterns of use in patients with schizophrenia: polypharmacy versus monotherapy.
Fisher MD; Reilly K; Isenberg K; Villa KF
BMC Psychiatry; 2014 Nov; 14():341. PubMed ID: 25433495
[TBL] [Abstract][Full Text] [Related]
2. Real-world effectiveness of antipsychotic monotherapy vs. polypharmacy in schizophrenia: to switch or to combine? A nationwide study in Hungary.
Katona L; Czobor P; Bitter I
Schizophr Res; 2014 Jan; 152(1):246-54. PubMed ID: 24275583
[TBL] [Abstract][Full Text] [Related]
3. Prevalence, utilization patterns, and predictors of antipsychotic polypharmacy: experience in a multistate Medicaid population, 1998-2003.
Morrato EH; Dodd S; Oderda G; Haxby DG; Allen R; Valuck RJ
Clin Ther; 2007 Jan; 29(1):183-95. PubMed ID: 17379060
[TBL] [Abstract][Full Text] [Related]
4. The risks and benefits of switching patients with schizophrenia or schizoaffective disorder from two to one antipsychotic medication: a randomized controlled trial.
Constantine RJ; Andel R; McPherson M; Tandon R
Schizophr Res; 2015 Aug; 166(1-3):194-200. PubMed ID: 26141142
[TBL] [Abstract][Full Text] [Related]
5. Trends in and Predictors of Long-Term Antipsychotic Polypharmacy Use Among Ohio Medicaid Patients with Schizophrenia, 2008-2014.
Fontanella CA; Hiance-Steelesmith DL; Guirgis H; Campo JV
Psychiatr Serv; 2018 Sep; 69(9):1015-1020. PubMed ID: 29962308
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of switching from antipsychotic polypharmacy to monotherapy.
Essock SM; Schooler NR; Stroup TS; McEvoy JP; Rojas I; Jackson C; Covell NH;
Am J Psychiatry; 2011 Jul; 168(7):702-8. PubMed ID: 21536693
[TBL] [Abstract][Full Text] [Related]
7. Association of Antipsychotic Polypharmacy vs Monotherapy With Psychiatric Rehospitalization Among Adults With Schizophrenia.
Tiihonen J; Taipale H; Mehtälä J; Vattulainen P; Correll CU; Tanskanen A
JAMA Psychiatry; 2019 May; 76(5):499-507. PubMed ID: 30785608
[TBL] [Abstract][Full Text] [Related]
8. Outcomes of medicaid beneficiaries with schizophrenia receiving clozapine only or antipsychotic combinations.
Velligan DI; Carroll C; Lage MJ; Fairman K
Psychiatr Serv; 2015 Feb; 66(2):127-33. PubMed ID: 25321616
[TBL] [Abstract][Full Text] [Related]
9. Antipsychotic polypharmacy and high-dose prescription in schizophrenia: a 5-year comparison.
Roh D; Chang JG; Kim CH; Cho HS; An SK; Jung YC
Aust N Z J Psychiatry; 2014 Jan; 48(1):52-60. PubMed ID: 23671214
[TBL] [Abstract][Full Text] [Related]
10. Antipsychotic polypharmacy in the treatment of schizophrenia in China and Japan.
Qiu H; He Y; Zhang Y; He M; Liu J; Chi R; Si T; Wang H; Dong W
Aust N Z J Psychiatry; 2018 Dec; 52(12):1202-1212. PubMed ID: 30309245
[TBL] [Abstract][Full Text] [Related]
11. The evolution of antipsychotic switch and polypharmacy in natural practice--a longitudinal perspective.
Tsutsumi C; Uchida H; Suzuki T; Watanabe K; Takeuchi H; Nakajima S; Kimura Y; Tsutsumi Y; Ishii K; Imasaka Y; Kapur S
Schizophr Res; 2011 Aug; 130(1-3):40-6. PubMed ID: 21624824
[TBL] [Abstract][Full Text] [Related]
12. Antipsychotic monotherapy and polypharmacy in the treatment of outpatients with schizophrenia in the European Schizophrenia Outpatient Health Outcomes Study.
Novick D; Ascher-Svanum H; Brugnoli R; Bertsch J; Hong J; Haro JM
J Nerv Ment Dis; 2012 Jul; 200(7):637-43. PubMed ID: 22759944
[TBL] [Abstract][Full Text] [Related]
13. Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998-2000.
Ganguly R; Kotzan JA; Miller LS; Kennedy K; Martin BC
J Clin Psychiatry; 2004 Oct; 65(10):1377-88. PubMed ID: 15491242
[TBL] [Abstract][Full Text] [Related]
14. Antipsychotic polypharmacy in schizophrenia patients in China and its association with treatment satisfaction and quality of life: findings of the third national survey on use of psychotropic medications in China.
Li Q; Xiang YT; Su YA; Shu L; Yu X; Chiu HF; Correll CU; Ungvari GS; Lai KY; Ma C; Wang GH; Bai PS; Li T; Sun LZ; Shi JG; Chen XS; Mei QY; Li KQ; Si TM
Aust N Z J Psychiatry; 2015 Feb; 49(2):129-36. PubMed ID: 24923760
[TBL] [Abstract][Full Text] [Related]
15. Assessment of inpatient psychiatric readmission risk among patients discharged on an antipsychotic polypharmacy regimen: A retrospective cohort study.
Boskailo E; Malkoc A; McCurry DB; Venter J; Drachman D; Ramos GM
Acta Med Acad; 2017 Nov; 46(2):133-144. PubMed ID: 29338277
[TBL] [Abstract][Full Text] [Related]
16. Antipsychotic polypharmacy and risk of death from natural causes in patients with schizophrenia: a population-based nested case-control study.
Baandrup L; Gasse C; Jensen VD; Glenthoj BY; Nordentoft M; Lublin H; Fink-Jensen A; Lindhardt A; Mortensen PB
J Clin Psychiatry; 2010 Feb; 71(2):103-8. PubMed ID: 19895781
[TBL] [Abstract][Full Text] [Related]
17. Real-World Evidence of Antipsychotic Monotherapy Versus Polypharmacy in the Treatment of Schizophrenia Spectrum Disorders.
Korkmaz ŞA; Koca E; Yilmaz Ö; Özbek T; Güçlü MA; Kizgin S
J Clin Psychopharmacol; 2024 May-Jun 01; 44(3):250-257. PubMed ID: 38489589
[TBL] [Abstract][Full Text] [Related]
18. Patterns of discontinuation of atypical antipsychotics in the province of Québec: A retrospective prescription claims database analysis.
Moisan J; Grégoire JP
Clin Ther; 2010; 32 Suppl 1():S21-31. PubMed ID: 20152549
[TBL] [Abstract][Full Text] [Related]
19. Antipsychotic prescribing pathways, polypharmacy, and clozapine use in treatment of schizophrenia.
Gören JL; Meterko M; Williams S; Young GJ; Baker E; Chou CH; Kilbourne AM; Bauer MS
Psychiatr Serv; 2013 Jun; 64(6):527-33. PubMed ID: 23450334
[TBL] [Abstract][Full Text] [Related]
20. A clinical case series of switching from antipsychotic polypharmacy to monotherapy with a second-generation agent on patients with chronic schizophrenia.
Suzuki T; Uchida H; Watanabe K; Yagi G; Kashima H
Prog Neuropsychopharmacol Biol Psychiatry; 2004 Mar; 28(2):361-9. PubMed ID: 14751434
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
